Reuters logo
BRIEF-OMEROS REPORTS ADDITIONAL POSITIVE DATA FOR OMS721
October 26, 2017 / 5:19 PM / a month ago

BRIEF-OMEROS REPORTS ADDITIONAL POSITIVE DATA FOR OMS721

Oct 26 (Reuters) - Omeros Corp:

* OMEROS REPORTS ADDITIONAL AND CONSISTENTLY POSITIVE DATA FOR OMS721 IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY

* ‍OMS721 HAS BEEN WELL TOLERATED AND NO SAFETY CONCERNS HAVE BEEN IDENTIFIED​

* 3 OF 4 PATIENTS FOR WHOM OMS721 TREATMENT WAS DISCONTINUED EARLY EXPERIENCED DETERIORATION OF THEIR CONDITIONS AND SUBSEQUENTLY DIED​

* ‍PREPARING TO INITIATE OMS721 PHASE 3 CLINICAL TRIAL, PURSUING FDA‘S BREAKTHROUGH THERAPY DESIGNATION, EUROPEAN MEDICINES AGENCY‘S PRIME STATUS​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below